[HTML][HTML] Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
C Marini, T Maia, R Bergantim, J Pires, E Aguiar… - Annals of …, 2019 - Springer
Autologous stem cell transplantation (ASCT) is still debatable in treatment of patients over
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
C Marini, T Maia, R Bergantim, J Pires… - Annals of …, 2019 - pubmed.ncbi.nlm.nih.gov
Autologous stem cell transplantation (ASCT) is still debatable in treatment of patients over
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
C Marini, T Maia, R Bergantim, J Pires… - Annals of …, 2018 - europepmc.org
Autologous stem cell transplantation (ASCT) is still debatable in treatment of patients over
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
[PDF][PDF] Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
C Marini - multiplemyeloma.org.nz
Patients with newly diagnosed MM who had undergone autologous SCT (n= 132) were
compared with 23 nontransplanted patients with similar clinical characteristics for this …
compared with 23 nontransplanted patients with similar clinical characteristics for this …
[HTML][HTML] Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
C Marini, T Maia, R Bergantim, J Pires… - Annals of …, 2019 - ncbi.nlm.nih.gov
Autologous stem cell transplantation (ASCT) is still debatable in treatment of patients over
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
[PDF][PDF] Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
C Marini, T Maia, R Bergantim, J Pires… - Annals of …, 2019 - scienceopen.com
Autologous stem cell transplantation (ASCT) is still debatable in treatment of patients over
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
C Marini, T Maia, R Bergantim, J Pires… - Annals of …, 2019 - search.proquest.com
Autologous stem cell transplantation (ASCT) is still debatable in treatment of patients over
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …
[PDF][PDF] Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
C Marini - multiplemyeloma.org.nz
Patients with newly diagnosed MM who had undergone autologous SCT (n= 132) were
compared with 23 nontransplanted patients with similar clinical characteristics for this …
compared with 23 nontransplanted patients with similar clinical characteristics for this …